[141 Similarly, neither Dr. Burzynski nor his patients have alleged facts suggest- ing that the FDA has acted improperly by denying antineoplaston AIO IND status. Although, in his brief before this court, Dr. Burzynski contends that he has never ar- gued that he is entitled to IND status for his new